Hospital De Sagunto
- Address
- lock Available on a paid plan
Digestive System Diseases
At Hospital De Sagunto’s intensive care unit, researchers are investigating new therapeutic options for chronic inflammatory bowel conditions.
- Long‑term efficacy of monoclonal antibody
- Safety monitoring in chronic use
- Patient‑reported outcome assessments
The primary goal is to determine whether long‑term use of a novel monoclonal antibody can improve disease control in patients with ulcerative colitis, while monitoring safety and quality of life.
Immune System Diseases
The ICU team is focused on autoimmune kidney diseases, testing agents that may halt disease progression.
- Complete renal response evaluation
- Proteinuria reduction strategies
- Safety profile of oral inhibitors
Trials aim to achieve a complete renal response in individuals with lupus nephritis and to reduce protein loss in those with Immunoglobulin A nephropathy, thereby preserving kidney function.
Neoplasms
Early‑stage breast cancer patients are enrolled to assess innovative strategies that could lower recurrence risk.
- Circulating tumor DNA as MRD marker
- Adjuvant therapy effectiveness
- Disease clearance rates
By measuring minimal residual disease through circulating tumor DNA, the study seeks to demonstrate that targeted therapy can improve outcomes for breast cancer patients.
Respiratory Tract Diseases
Allergic airway disorders are being treated with novel immunotherapy approaches designed for long‑term symptom relief.
- Subcutaneous polymerised allergen extracts
- Placebo‑controlled symptom scoring
- Impact on asthma control
The investigation compares subcutaneous polymerised extracts with placebo to evaluate symptom reduction in allergic rhinitis and its effect on coexisting asthma.
Pathological Conditions, Signs and Symptoms
Critical care research at the site aims to improve weaning strategies for patients dependent on ventilatory support.
- Predictors of successful extubation
- Non‑invasive ventilation vs high‑flow oxygen
- Standardised weaning protocols
The objective is to lower the rate of extubation failure and to define optimal protocols for transitioning from mechanical ventilation to spontaneous breathing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Novartis Pharma AG2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital De Sagunto
lock Showing 1 of 9 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Exemestane | 2 | Unknown | 2018-01-10 | 2023-07-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.